Imaging of tumors using a specific PET scan agent

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the uptake of the imaging agent [68Ga]-pentixafor in patients with various hematologic malignancies and solid tumors through PET/CT scans. It focuses on individuals with conditions such as non-Hodgkin lymphoma, multiple myeloma, and specific histiocytic neoplasms. The study will include treatment-naïve, therapy-refractory, or relapsed patients to assess the effectiveness of this imaging technique in identifying tumor presence and characteristics. A total of twenty patients will be enrolled based on specific eligibility criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Twenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed blood cancers meeting the below criteria will be included:

* Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) or Non-Hodgkin lymphoma with variable FDG uptake and clinical course, such as mantle cell lymphoma; and measurable disease according to Lugano criteria

or

* Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD)
* MGUS/SMM or MM according to IMWG definitions
* Solid tumors, such as lung cancers, meningioma, adrenocortical neoplasms including cortisol-producing adenomas or high suspicion for tumor, such as in patients with Cushing's disease.
* Age ≥18
* Negative serum pregnancy test for female volunteers of childbearing age and potential (as defined by MSKCC Standards \& Guidelines) from assays obtained \<2 weeks prior to study enrollment/intervention; or negative urine pregnancy test performed on the day of intervention
* MSKCC patients

Exclusion Criteria:

* Breast-feeding
* History of renal functional disorders (chronic kidney disease with eGFR\<30)
* Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)

Where it's running

• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Anton Nosov, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Anton Nosov, MD
• Email: nosova@mskcc.org
• Phone: 212-639-8575

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• See if a behavioral coaching plus at-home exercise can help older blood cancer survivors slow aging

  Aimed at people 50 and older who have had a blood cancer, this trial tests whether combining coaching with a virtual exercise program can help slow aging and improve health.

  Recruiting University of Nebraska · Omaha, Nebraska · NCT07292272

• Voice monitoring for side effects during CAR T-cell therapy

  This project will test whether twice-daily smartphone voice recordings and brief daily neurologic checks can spot early neurologic side effects in adults receiving FDA-approved CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07249528

• Mozobil (plerixafor) to mobilize stem cells for autologous transplant

  This trial will test whether starting with G‑CSF and giving Plerixafor only when needed can collect enough stem cells for adults with multiple myeloma or lymphoma undergoing autologous transplant while possibly lowering engraftment syndrome.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07188090

• Evaluating the risk of blood cancers in firefighters

  This study is testing if firefighters who have been exposed to harmful substances are at a higher risk for blood cancers and related conditions.

  Recruiting Wake Forest University Health Sciences · Charlotte, North Carolina · NCT06870760

• Using Darzalex Faspro to lower antibody levels before stem cell transplant

  This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06398457

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.